[Translation] An open-label, multicenter, dose-escalation and dose-expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of SCTB41 in the treatment of patients with advanced malignant solid tumors
Ia期:主要评估SCTB41单药在晚期恶性实体瘤患者中的安全性和耐受性。
Ib期:确定SCTB41单药在晚期恶性实体瘤患者中的II期推荐剂量(RP2D)并评估初步抗肿瘤活性及安全性。
Ⅱ期:评估SCTB41单药在晚期恶性实体瘤(特定瘤种)患者中的初步疗效。
[Translation] Phase Ia: Mainly evaluate the safety and tolerability of SCTB41 monotherapy in patients with advanced malignant solid tumors.
Phase Ib: Determine the Phase II recommended dose (RP2D) of SCTB41 monotherapy in patients with advanced malignant solid tumors and evaluate the preliminary anti-tumor activity and safety.
Phase II: Evaluate the preliminary efficacy of SCTB41 monotherapy in patients with advanced malignant solid tumors (specific tumor types).